AU2010207486B2 - Bicyclic heterocyclic spiro compounds - Google Patents

Bicyclic heterocyclic spiro compounds Download PDF

Info

Publication number
AU2010207486B2
AU2010207486B2 AU2010207486A AU2010207486A AU2010207486B2 AU 2010207486 B2 AU2010207486 B2 AU 2010207486B2 AU 2010207486 A AU2010207486 A AU 2010207486A AU 2010207486 A AU2010207486 A AU 2010207486A AU 2010207486 B2 AU2010207486 B2 AU 2010207486B2
Authority
AU
Australia
Prior art keywords
dimethyl
indol
dec
oxa
diazaspiro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010207486A
Other languages
English (en)
Other versions
AU2010207486A1 (en
Inventor
Nira Bar-Ner
Abraham Fisher
Victoria Nachum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Israel Institute for Biological Research
Original Assignee
Israel Institute for Biological Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Israel Institute for Biological Research filed Critical Israel Institute for Biological Research
Publication of AU2010207486A1 publication Critical patent/AU2010207486A1/en
Application granted granted Critical
Publication of AU2010207486B2 publication Critical patent/AU2010207486B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2010207486A 2009-01-26 2010-01-26 Bicyclic heterocyclic spiro compounds Active AU2010207486B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14714309P 2009-01-26 2009-01-26
US61/147,143 2009-01-26
PCT/IL2010/000064 WO2010084499A2 (en) 2009-01-26 2010-01-26 Bicyclic heterocyclic spiro compounds

Publications (2)

Publication Number Publication Date
AU2010207486A1 AU2010207486A1 (en) 2011-09-15
AU2010207486B2 true AU2010207486B2 (en) 2013-03-07

Family

ID=42291285

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010207486A Active AU2010207486B2 (en) 2009-01-26 2010-01-26 Bicyclic heterocyclic spiro compounds

Country Status (12)

Country Link
US (1) US8673931B2 (enExample)
EP (1) EP2389383B1 (enExample)
JP (2) JP5874878B2 (enExample)
KR (2) KR20150116466A (enExample)
CN (1) CN102361876B (enExample)
AU (1) AU2010207486B2 (enExample)
BR (1) BRPI1007350B8 (enExample)
CA (1) CA2750777C (enExample)
NZ (1) NZ594768A (enExample)
RU (1) RU2506266C2 (enExample)
WO (1) WO2010084499A2 (enExample)
ZA (1) ZA201106221B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010084499A2 (en) * 2009-01-26 2010-07-29 Israel Institute For Biological Research Bicyclic heterocyclic spiro compounds
JP5909070B2 (ja) * 2010-10-28 2016-04-26 国立大学法人 東京大学 Ｇｓ共役受容体に対する医薬品候補化合物をスクリーニングする方法
EP2882428B1 (en) * 2012-07-13 2019-01-16 Pain Therapeutics, Inc. A method of inhibiting tau phosphorylation
WO2014113893A1 (en) * 2013-01-28 2014-07-31 University Of Manitoba Use of galantamine and related compounds for treatment of inflammatory bowel diseases
GB201504675D0 (en) * 2015-03-19 2015-05-06 Heptares Therapeutics Ltd Pharmaceutical compounds
RU2604878C1 (ru) * 2015-11-17 2016-12-20 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" 7-АМИНО-2,2',4-ТРИОКСО-5'-ФЕНИЛ-1,1',2,2',3,4-ГЕКСАГИДРОСПИРО{ПИРАНО[2,3-d]ПИРИМИДИН-5,3'-ПИРРОЛ}-6-КАРБОНИТРИЛЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ
WO2019180224A1 (en) 2018-03-22 2019-09-26 Nsc Therapeutics Gmbh Compounds and methods for use in the treatment of microglia-mediated disorders
PH12022550860A1 (en) * 2019-10-09 2023-06-14 Novartis Ag 5-oxa-2-azaspiro[3.4]octane derivatives as m4 agonists
UY38906A (es) 2019-10-09 2021-05-31 Novartis Ag Compuestos 2- derivados de azaspiro[3,4]octano como agonistas de m4 y composiciones de los mismos
EP4137496A4 (en) * 2020-05-12 2024-08-21 Beijing Greatway Pharmaceutical Technology Co., Ltd. COMPOUND FOR ADJUSTING NMDA RECEPTOR ACTIVITY, ASSOCIATED PHARMACEUTICAL COMPOSITION AND USE
CA3263540A1 (en) * 2022-07-29 2024-02-01 Anavex Life Sciences Corp. Compositions and methods for the prevention of cognitive decline caused by degenerative diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3481942A (en) * 1968-09-06 1969-12-02 Smithkline Corp Oxa-diazaspiro(4.5)decane compounds
WO1990015804A1 (en) * 1989-06-21 1990-12-27 Fisons Corporation Novel spirofurane derivatives
US5221675A (en) * 1989-12-15 1993-06-22 Abbott Laboratories Aza-spirocyclic compounds that enhance cholinergic neurotransmission
WO1995003303A2 (en) * 1993-07-20 1995-02-02 State Of Israel, Represented By The Prime Minister's Office, Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60208590A (ja) * 1984-03-30 1985-10-21 株式会社日立製作所 エレベ−タ−敷居装置
EP0189370A3 (de) * 1985-01-16 1988-01-27 Sandoz Ag Spiro-dioxolane, -dithiolane und -oxothiolane
DE3501225A1 (de) * 1985-01-16 1986-07-24 Sandoz-Patent-GmbH, 7850 Lörrach Spirodioxolane, ihre herstellung und verwendung
US4855290A (en) * 1985-05-10 1989-08-08 State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research Derivatives of quinuclidine
US5179079A (en) 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
JPS63208590A (ja) 1987-02-24 1988-08-30 Yamanouchi Pharmaceut Co Ltd ヘテロ環式スピロ化合物及びその製造法
JPS63208844A (ja) * 1987-02-26 1988-08-30 Konica Corp 有機着色物質の光褪色防止方法
IL87234A (en) * 1987-08-13 1992-02-16 Israel Inst Biolog Res Optical isomers of 2-methylspiro(1,3-oxathiolane-5,3')quinuclidine,their preparation and pharmaceutical compositions containing them
US4981858A (en) 1987-08-13 1991-01-01 State Of Israel, Represented By The Prime Minister's Office, Israel Institute For Biological Research Optical isomers
ATE122353T1 (de) * 1987-10-05 1995-05-15 Yamanouchi Pharma Co Ltd Heterozyklische spiroverbindungen und ihre herstellung.
US4876260A (en) 1987-10-28 1989-10-24 State Of Israel, Israel Institute Of Biological Research Oxathiolanes
US4900830A (en) 1987-10-28 1990-02-13 Israel Institute For Biological Research Process for labelling sulfur-containing compounds
IT1223343B (it) 1987-11-03 1990-09-19 Also Lab Sas Formulazioni farmaceutiche per somministrazione transdermica
GB8808433D0 (en) * 1988-04-11 1988-05-11 Merck Sharp & Dohme Therapeutic agents
GB8816299D0 (en) * 1988-07-08 1988-08-10 Merck Sharp & Dohme Therapeutic agents
US5053412A (en) 1990-04-10 1991-10-01 Israel Institute For Biological Research Spiro nitrogen-bridged heterocyclic compounds
JPH02164882A (ja) * 1988-12-20 1990-06-25 Yamanouchi Pharmaceut Co Ltd スピロ化合物及びその中間体
US4994439A (en) 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
EP0460064A4 (en) 1989-02-23 1992-04-01 Rorer International (Holdings) Inc. Therapeutic aerosol formulations
GB8921222D0 (en) 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
US5407938A (en) * 1990-04-10 1995-04-18 Israel Institute For Biological Research Certain 1-methyl-piperidine-4-spiro-4'-(1'-3'-oxazolines) and corresponding -(1',3' thiazolines)
IL97726A (en) * 1990-04-10 1994-12-29 Israel Inst Biolog Res Pharmaceutical compositions containing compounds with bridged and unbridged heterocyclic groups, spiro-connected with oxazoline and thiazoline groups, and some new such compounds
US5852029A (en) 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
US5230884A (en) 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
US5292499A (en) 1990-09-11 1994-03-08 University Of Wales College Of Cardiff Method of preparing medical aerosol formulations including drug dissolved in reverse micelles
US5403931A (en) * 1991-05-15 1995-04-04 Yamanouchi Pharmaceutical Co., Ltd. (-)-(S)-2,8-dimethyl-3-methylene-1-oxa-8-azaspiro[4.5]decane L-tartrate
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US5707641A (en) 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
CH689139A5 (de) 1995-04-03 1998-10-30 Cerbios Pharma Sa Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung.
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US5635161A (en) 1995-06-07 1997-06-03 Abbott Laboratories Aerosol drug formulations containing vegetable oils
US6120794A (en) 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
ATE243998T1 (de) 1995-10-12 2003-07-15 Supergen Inc Liposomformulierung von 5-beta steroiden
DE19637043A1 (de) * 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Neue Aminoalkoholderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel und Reagenzien
JP2002535242A (ja) 1998-05-20 2002-10-22 ザ リポソーム カンパニー、インコーポレーテッド 新規な粒子状剤型
US6451349B1 (en) 1998-08-19 2002-09-17 Quadrant Healthcare (Uk) Limited Spray-drying process for the preparation of microparticles
GB9814172D0 (en) 1998-06-30 1998-08-26 Andaris Ltd Formulation for inhalation
AUPP494798A0 (en) 1998-07-29 1998-08-20 Pacific Biolink Pty Limited Protective protein formulation
US6290987B1 (en) 1998-09-27 2001-09-18 Generex Pharmaceuticals, Inc. Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
WO2000023444A1 (en) * 1998-10-21 2000-04-27 Abbott Laboratories 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
US6294153B1 (en) 1998-12-21 2001-09-25 Generex Pharmaceuticals, Inc. Aerosol pharmaceutical formulation for pulmonary and nasal delivery
EP1338272A1 (en) 1998-12-21 2003-08-27 Generex Pharmaceuticals Inc. Aerosol formulations for buccal and pulmonary application comprising chenodeoxycholate or deoxycholate
US6436367B1 (en) 1998-12-21 2002-08-20 Generex Pharmaceuticals Inc. Aerosol formulations for buccal and pulmonary application
AU780397B2 (en) 1999-02-03 2005-03-17 Powderject Research Limited Hydrogel particle formulations
JP2002538195A (ja) 1999-03-08 2002-11-12 パウダージェクト リサーチ リミテッド 生物活性化合物の持続放出用の無針注射器を使用する微粒子製剤の送達
AU3957400A (en) 1999-04-16 2000-11-02 Novo Nordisk A/S Dry, mouldable drug formulation
AU5936400A (en) 1999-06-04 2000-12-28 Delrx Pharmaceutical Corporation Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
CA2382821A1 (en) 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US20010036481A1 (en) 1999-08-25 2001-11-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
BR0107764A (pt) 2000-01-20 2002-11-12 Basilea Pharmaceutica Ag Composições de peptìdeo cìclico nasalmente administráveis
EP1129705A1 (en) 2000-02-17 2001-09-05 Rijksuniversiteit te Groningen Powder formulation for inhalation
GB0009468D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
JP2004500424A (ja) 2000-04-17 2004-01-08 ヴェクトゥラ　リミテッド 吸入器で使用するための製剤
WO2002019989A2 (en) 2000-09-08 2002-03-14 Powderject Research Limited Alginate particle formulation
FI20002768L (fi) 2000-12-18 2002-06-19 Licentia Oy Enteropäällysteisiä lääkekoostumuksia ja niiden valmistus
GB0107106D0 (en) 2001-03-21 2001-05-09 Boehringer Ingelheim Pharma Powder inhaler formulations
DE10130020A1 (de) * 2001-06-25 2003-12-04 Gruenenthal Gmbh Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate
US20030019437A1 (en) 2001-07-26 2003-01-30 John Fore Ungulate game animal feed system and method
US20030064033A1 (en) 2001-08-16 2003-04-03 Brown Larry R. Propellant-based microparticle formulations
WO2003072080A1 (en) 2002-02-22 2003-09-04 Advanced Inhalation Research, Inc. Inhalable formulations for sustained release
CA2478974C (en) 2002-03-20 2014-12-16 Advanced Inhalation Research, Inc. Inhalable sustained therapeutic formulations
JP4584706B2 (ja) 2002-05-03 2010-11-24 イスラエル インスティチュート フォー バイオロジカル リサーチ 中枢及び末梢神経系障害を治療するための方法及び組成物、並びにそれらに有用な新規の化合物
DE60307082D1 (de) 2002-05-07 2006-09-07 Ferring Bv In der mundhöhle dispergierbare phamarzeutische zusammensetzung mit desmopressin
DE10323244A1 (de) 2003-05-22 2004-12-16 Infineon Technologies Ag Integrierte Speicher-Schaltungsanordnung, insbesondere UCP-Flash-Speicher
DE102005030051A1 (de) * 2005-06-27 2006-12-28 Grünenthal GmbH Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
JP2010155827A (ja) * 2008-12-04 2010-07-15 Takeda Chem Ind Ltd スピロ環化合物
WO2010084499A2 (en) * 2009-01-26 2010-07-29 Israel Institute For Biological Research Bicyclic heterocyclic spiro compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3481942A (en) * 1968-09-06 1969-12-02 Smithkline Corp Oxa-diazaspiro(4.5)decane compounds
WO1990015804A1 (en) * 1989-06-21 1990-12-27 Fisons Corporation Novel spirofurane derivatives
US5221675A (en) * 1989-12-15 1993-06-22 Abbott Laboratories Aza-spirocyclic compounds that enhance cholinergic neurotransmission
WO1995003303A2 (en) * 1993-07-20 1995-02-02 State Of Israel, Represented By The Prime Minister's Office, Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
AGER, J. H. ET AL., Journal of Pharmaceutical Sciences, 1969, vol. 58(4), pages 499-500. *
CAS Registry Number 1010934-47-0, Entered STN 30 March 2008 *
CAS Registry Number 1026890-94-7, Entered STN 10 Jun 2008 *
CAS Registry Number 942833-24-1, Entered STN 19 July 2007 *
CAS Registry Number 951928-66-8, Entered STN 30 October 2007 *
CAS Registry Number 951954-41-9, Entered STN 30 October 2007 *
CAS Registry Number 951965-19-8, Entered STN 30 October 2007 *
CAS Registry Number 951977-71-2, Entered STN 30 October 2007 *
CAS Registry Number 951996-61-5, Entered STN 30 October 2007 *
KAMETANI, T. ET AL., Chemical & Pharmaceutical Bulletin, 1970, vol. 18(6), pages 1161-7. *

Also Published As

Publication number Publication date
WO2010084499A2 (en) 2010-07-29
JP2012515763A (ja) 2012-07-12
NZ594768A (en) 2013-02-22
JP5874878B2 (ja) 2016-03-02
EP2389383A2 (en) 2011-11-30
EP2389383B1 (en) 2019-04-24
KR20150116466A (ko) 2015-10-15
US8673931B2 (en) 2014-03-18
CA2750777A1 (en) 2010-07-29
CN102361876A (zh) 2012-02-22
AU2010207486A1 (en) 2011-09-15
CN102361876B (zh) 2015-02-04
KR101675174B1 (ko) 2016-11-10
CA2750777C (en) 2018-04-03
ZA201106221B (en) 2013-04-24
BRPI1007350B1 (pt) 2020-11-17
WO2010084499A9 (en) 2010-12-09
BRPI1007350B8 (pt) 2021-05-25
BRPI1007350A2 (pt) 2018-03-06
WO2010084499A3 (en) 2010-10-21
RU2011134290A (ru) 2013-03-10
RU2506266C2 (ru) 2014-02-10
US20110281903A1 (en) 2011-11-17
JP2015172098A (ja) 2015-10-01
KR20110127160A (ko) 2011-11-24

Similar Documents

Publication Publication Date Title
EP2389383B1 (en) Bicyclic heterocyclic spiro compounds
US11834407B2 (en) Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists
US11014880B2 (en) Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists
CN107406449B (zh) 作为毒蕈碱m1受体和/或m4受体的激动剂的螺环化合物
CN109661396B (zh) 作为rock抑制剂的螺稠合环状脲
CN110903306B (zh) 毒蕈碱受体激动剂
US11773090B2 (en) Pharmaceutical compounds
US9034891B2 (en) Bicyclic heterocyclic spiro compounds
CZ295929B6 (cs) Léčivo obsahující azaspirosloučeninu pro léčení onemocnění centrálního nebo periferního nervového systému, enantiomer azaspirosloučeniny a farmaceutický přípravek ho obsahující
TW201202251A (en) Substituted N-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)